Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Altoona Center for Clinical Research
mi
from
Duncansville, PA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
PMA Medical Specialists, LLC
mi
from
Limerick, PA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
PMA Medical Specialists, LLC
mi
from
Limerick, PA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Methodist Healthcare
mi
from
Memphis, TN
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Methodist Healthcare
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Ramesh C. Gupta, M.D.
mi
from
Memphis, TN
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Ramesh C. Gupta, M.D.
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Austin Regional Clinic
mi
from
Austin, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Austin Regional Clinic
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Pioneer Research Solutions
mi
from
Cypress, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Pioneer Research Solutions
mi
from
Cypress, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arthritis Care and Diagnostic Center
mi
from
Dallas, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arthritis Care and Diagnostic Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Accurate Clinical Research
mi
from
Houston, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Accurate Clinical Research
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Houston Institute for Clinical Research
mi
from
Houston, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Houston Institute for Clinical Research
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arthritis & Osteoporosis Associates, LLP
mi
from
Lubbock, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arthritis & Osteoporosis Associates, LLP
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Accurate Clinical Research, Inc.
mi
from
Nassau Bay, TX
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Accurate Clinical Research, Inc.
mi
from
Nassau Bay, TX
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Apex Clinical Research
mi
from
Kennewick, WA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Apex Clinical Research
mi
from
Kennewick, WA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Swedish Medical Center
mi
from
Seattle, WA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arthritis Northwest Rheumatology
mi
from
Spokane, WA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arthritis Northwest Rheumatology
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Rheumatology and Immunotherapy Center
mi
from
Franklin, WI
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Rheumatology and Immunotherapy Center
mi
from
Franklin, WI
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Florida Medical Clinic
mi
from
Zephyrhills, FL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Florida Medical Clinic
mi
from
Zephyrhills, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Center of Reading, LLC
mi
from
Wyomissing, PA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Center of Reading, LLC
mi
from
Wyomissing, PA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Pennsylvania Regional Center for Arthritis & Osteoarthritis
mi
from
Wyomissing, PA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Pennsylvania Regional Center for Arthritis & Osteoarthritis
mi
from
Wyomissing, PA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
mi
from
Camperdown,
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
mi
from
Camperdown,
Click here to add this to my saved trials
Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra- Articularly in Patients With Osteoarthritis
Status: Enrolling
Updated:  11/21/2017
Ageless Institute
mi
from
Aventura, FL
Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra- Articularly in Patients With Osteoarthritis
Status: Enrolling
Updated: 11/21/2017
Ageless Institute
mi
from
Aventura, FL
Click here to add this to my saved trials
A Study With GLPG1972 in Osteoarthritis Subjects
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Doses of GLPG1972 for 4 Weeks in Subjects With Osteoarthritis
Status: Enrolling
Updated:  11/21/2017
Covance-Daytona Beach
mi
from
Daytona Beach, FL
A Study With GLPG1972 in Osteoarthritis Subjects
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Doses of GLPG1972 for 4 Weeks in Subjects With Osteoarthritis
Status: Enrolling
Updated: 11/21/2017
Covance-Daytona Beach
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
New York, NY
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
Duncansville, PA
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
Duncansville, PA
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
Glostrup,
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
Glostrup,
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Glendale, AZ
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Glendale, AZ
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Mesa, AZ
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
La Palma, CA
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
La Palma, CA
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Granger, IN
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Granger, IN
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Saint Louis, MO
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Saint Louis, MO
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Orchard Park, NY
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Orchard Park, NY
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Salisbury, NC
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Salisbury, NC
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Middleburg Heights, OH
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Duncansville, PA
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Austin, TX
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Houston, TX
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  11/28/2017
Site Reference ID/Investigator# 128791
mi
from
Maroochydore,
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 11/28/2017
Site Reference ID/Investigator# 128791
mi
from
Maroochydore,
Click here to add this to my saved trials
The Knee Usual Care Evaluation Study
Title: The Study of Intra-articular Interventions of Platelet Rich Plasma or Hyaluronic Acid Compounds vs. Usual Care (Exercise/Diet/Supplements) in the Medical Management of Knee OA- Effects on Pain and Function; Effects on Articular Cartilage; Effects on Time to Partial or Total Knee Arthroplasty: The Knee Usual Care Evaluation (KUCE) Study
Status: Enrolling
Updated:  11/29/2017
Hospital for Special Surgery
mi
from
New York, NY
The Knee Usual Care Evaluation Study
Title: The Study of Intra-articular Interventions of Platelet Rich Plasma or Hyaluronic Acid Compounds vs. Usual Care (Exercise/Diet/Supplements) in the Medical Management of Knee OA- Effects on Pain and Function; Effects on Articular Cartilage; Effects on Time to Partial or Total Knee Arthroplasty: The Knee Usual Care Evaluation (KUCE) Study
Status: Enrolling
Updated: 11/29/2017
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Inflammation and the Heart
Inflammation and the Heart
Status: Enrolling
Updated:  11/30/2017
Vanderbilt
mi
from
Nashville, TN
Inflammation and the Heart
Inflammation and the Heart
Status: Enrolling
Updated: 11/30/2017
Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Pinnacle Research Group; Llc, Central
mi
from
Anniston, AL
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Pinnacle Research Group; Llc, Central
mi
from
Anniston, AL
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Uni Of Alabama,Birmingham; Medicine - Rheumatology
mi
from
Birmingham, AL
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Uni Of Alabama,Birmingham; Medicine - Rheumatology
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Clnical & Translational Reseach Center for Alabama, PC
mi
from
Tuscaloosa, AL
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Clnical & Translational Reseach Center for Alabama, PC
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Arizona Arthritis & Rheumatology Associates, PC
mi
from
Glendale, AZ
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Arizona Arthritis & Rheumatology Associates, PC
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Arizona Arthritis & Rheumatology Research, PLLC
mi
from
Mesa, AZ
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Arizona Arthritis & Rheumatology Research, PLLC
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Arizona Arthritis and Rheuma
mi
from
Mesa, AZ
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Arizona Arthritis and Rheuma
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated:  11/30/2017
Valley Arthritis Care, LLC
mi
from
Phoenix, AZ
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy
Status: Enrolling
Updated: 11/30/2017
Valley Arthritis Care, LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials